Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 15/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540169 | 1.00 | ADRB3 (0.47) | ADRB3POLBADRB1CNR1CNR2 | |
| SCHEMBL6540174 | 1.00 | ADRB3 (0.47) | ADRB3POLBADRB1CNR1CNR2 | |
| SCHEMBL6540547 | 0.94 | ADRB3 (0.49) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6540552 | 0.94 | ADRB3 (0.49) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6540543 | 0.94 | ADRB3 (0.49) | ADRB3ADRB1ADRB2 | |
| SCHEMBL4463530 | 0.86 | ADRB3 (0.49) | ADRB3ADRB1ADRB2 | |
| SCHEMBL4463534 | 0.86 | ADRB3 (0.49) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6804730 | 0.83 | ADRB3 (0.49) | ADRB3ADRB1 | |
| SCHEMBL6804724 | 0.83 | ADRB3 (0.49) | ADRB3ADRB1 | |
| SCHEMBL6541722 | 0.83 | CNR1 (0.40) | ADRB3ADRB1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | ADRB3 58/4885POLB 1231/4885ADRB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.